Biggest Chelsea Charms

Questions No MIR void 3 and 4


regard to the hairy, point to the FALSE statement:

1. Patients usually have splenomegaly and there is little palpable peripheral lymphadenopathy.
2. cytopenia is rare to find.
3. There characteristically positive for staining acid phosphatase is not inhibited by tartrate.
4. Initial treatment is usually splenectomy.
5. The most used drug of choice today are the purine analogues (2CDA, DCF), but not all cases are treated.

is normal to have tied up with this question, it was actually canceled. The hairy, or hairy cell leukemia, is a special type of LLC. There are few data that you have to stay with her, but very important because they are very typical: large splenomegaly without lymphadenopathy almost (Option 1 true) + pancytopenia unlike of other leukemias often present with increased blood cells (Option 2 false) + sucked dry of bone marrow (myelofibrosis secondary). Other features of this particular data are tricoleucocitos leukemia or hairy cell (named after the strange-shaped cytoplasmic projections hairs) positivity for CD-25 and Fatra (tartrate-resistant acid phosphatase) as option 3 is true. Although the standard treatment was splenectomy and the spleen was the organ where he lived most of the tumor mass, the current treatment of choice is cladribine or 2 - chlorodeoxyadenosine (2CDA). Pentostatin or deoxycoformycin (DCF) is also used sometimes induce complete remissions, both are analogs of purines (option 5 true). Today splenectomy is indicated if greater than 10 cm splenomegaly and moderate infiltration of the bone marrow (option 4 is false as well.) Therefore, the correct options could be both the 2 and 4, so it was canceled.


Which of the following antibiotic therapy alone is not sufficient in the management of cancer patients receiving chemotherapy with febrile neutropenia?:

1. Cefepime.
2. Ceftazidime.
3. Meropenem.
4. Imipenem.
5. Piperacillin-tazobactam .

Very difficult. Know the management of patients with febrile neutropenia. The first is to cover S. aureus and Pseudomonas, which is why choosing a beta-lactam, broad-spectrum (cefepime, carbapenems, piperacillin-tazobactam). However, if covering Psedomona ceztazidima is not first choice because it has low anti-staphylococcal activity. In any case this question was finally canceled.


(questions 121 and 137, drill 1, AMIR)